A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

Approximately 125 subjects will be enrolled. Subjects must have mild-to-moderate AD involving
at least 5% treatable %BSA assessed on Baseline/Day 1. Treatable %BSA will be defined as the
percent of a subject's total body surface area that is AD-involved, excluding the scalp.

In addition, a cohort of at least 16 of the 125 subjects will be included in a subgroup for
PK assessment. These subjects must have moderate AD and a minimum of 35% treatable %BSA,
excluding the scalp, and must complete all PK assessments to be included in the PK analysis.
Of these subjects, at least 3 subjects who are less than 9 months of age will be enrolled.
Subjects discontinuing for reasons other than treatment emergent adverse event ( TEAE) may be
replaced at the discretion of the sponsor to ensure 16 subjects complete the PK assessments.
Only selected study sites will participate in the PK assessment.

Scheduled study visits/telephone contacts for all subjects will occur at Screening (up to 28
days prior to Baseline/Day 1), Baseline/Day 1, Day 8, Day 15, Day 22, Day 29 (end of
treatment/early termination), Day 36, and Day 57 (end of study).

Inclusion Criteria:

Aged ≥ 3 months at the screening visit to < 24 months on baseline/Day 1, diagnosed with AD

Exclusion Criteria:

Subjects with any clinically significant dermatological condition or disease (including
active or potentially recurrent non-AD dermatological conditions that overlap with AD such
as Netherton Syndrome)